Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;49(4):565-579.
doi: 10.4093/dmj.2025.0278. Epub 2025 Jun 11.

Differences between Type 2 Diabetes Mellitus and Obesity Management: Medical, Social, and Public Health Perspectives

Affiliations
Review

Differences between Type 2 Diabetes Mellitus and Obesity Management: Medical, Social, and Public Health Perspectives

Soo Lim et al. Diabetes Metab J. 2025 Jul.

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are among the most urgent global public health challenges, yet differ markedly in recognition and management across medical, social, infrastructure, and policy domains. T2DM is supported by clear diagnostic criteria, defined treatment targets, and broad acceptance as a chronic disease. In contrast, obesity is assessed using imprecise metrics like body mass index, lacks standardized treatment goals, and is often misunderstood as a lifestyle issue rather than a chronic, relapsing disease. This misconception contributes to stigma, discrimination, and unrealistic patient expectations. T2DM receives substantial research funding, comprehensive clinical guidelines, and structured medical education, with strong support from large professional societies and multidisciplinary care models. Obesity care remains underfunded, inconsistently delivered, and underrepresented in medical training. Public health and policy efforts strongly favor T2DM, providing coordinated programs, insurance coverage, and regulatory oversight. Conversely, obesity is marginalized, with limited policy influence and a largely unregulated commercial weight-loss industry. Bridging these disparities requires adopting lessons from T2DM management-such as evidence-based guidelines, improved provider training, expanded insurance coverage, and public health strategies-to enhance obesity care and recognize it as a chronic disease requiring long-term, structured management.

Keywords: Chronic disease; Diabetes mellitus, type 2; Education, medical; Health policy; Healthcare disparities; Insurance coverage; Obesity.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

Soo Lim received research grants from Merck Sharp & Dohme, Novo Nordisk, and LG Chem; and honoraria as a consultant or speaker for AstraZeneca, Boehringer Ingelheim, Abbott, LG Chem, Daewoong Pharmaceutical, Chong Kun Dang Pharmaceutical, and Novo Nordisk. Arya M. Sharma received honoraria from Novo Nordisk, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Currax, Oviva, and Vivus. Ga Eun Nam reported no potential conflict of interest relevant to this article.

Figures

Fig. 1.
Fig. 1.
Type 2 diabetes mellitus vs. obesity: key differences in the medical aspect.
Fig. 2.
Fig. 2.
Type 2 diabetes mellitus vs. obesity: key differences in the social and public health aspect.
Fig. 3.
Fig. 3.
Lessons from type 2 diabetes mellitus for obesity treatment.
None

References

    1. GBD 2021 Adult BMI Collaborators Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405:813–38. - PMC - PubMed
    1. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JP, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221–62. - PMC - PubMed
    1. Gregg EW, Pratt A, Owens A, Barron E, Dunbar-Rees R, Slade ET, et al. The burden of diabetes-associated multiple long-term conditions on years of life spent and lost. Nat Med. 2024;30:2830–7. - PMC - PubMed
    1. Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400:1803–20. - PubMed
    1. Neeland IJ, Lim S, Tchernof A, Gastaldelli A, Rangaswami J, Ndumele CE, et al. Metabolic syndrome. Nat Rev Dis Primers. 2024;10:77. - PubMed